Clinical evaluation of the Heart Check system, a new quantitative measurement of fresh capillary BNP

Area of Science:

• Cardiology
• Biomarker Analysis
• Point-of-Care Diagnostics

Background:

• Heart failure (HF) management relies on accurate biomarker assessment.
• Rapid, point-of-care (POC) testing can improve clinical decision-making for HF patients.
• B-type natriuretic peptide (BNP) is a key biomarker for diagnosing and managing heart failure.

Purpose of the Study:

• To evaluate the clinical and analytical performance of the Alere™ Heart Check (AHC) test.
• To assess the utility of a rapid POC immunoassay for BNP measurement in fresh capillary whole blood.
• To compare the AHC test with a standard plasma-based BNP assay.

Main Methods:

• Simultaneous BNP measurements were performed using the AHC capillary whole blood test and a plasma-based Abbott architect system.
• 163 patients with stable chronic heart failure were included in the study.
• Performance metrics including correlation, precision, sensitivity, specificity, and predictive values were analyzed.

Main Results:

• A good correlation was observed between the AHC test and the plasma-based assay, with divergence noted at BNP levels >2000 pg/ml.
• The AHC test demonstrated relatively poor precision.
• Despite precision limitations, the AHC test showed equivalent sensitivity, specificity, and predictive values for assessing patient dyspnea and managing heart failure.

Conclusions:

• The Alere™ Heart Check (AHC) BNP test is a suitable point-of-care tool for heart failure management.
• The test provides valuable clinical information for patient assessment, despite its precision limitations.
• AHC facilitates rapid BNP measurement at the point of care, supporting timely clinical decisions.